Verici Dx Plc (LSE:VRCI) is a small-cap kidney-transplant diagnostics company whose lead blood test, Tutivia, has moved from launch to a first full year of sales, Medicare reimbursement and, since June 2026, clearance in all 50 US states. On 11 August 2026 it won Olink Certified Service Provider status, letting its Pennsylvania laboratory sell proteomics services to drug developers.
The question is whether that commercial momentum can outrun the balance sheet. The FY25 accounts, published on 29 June 2026, carry a material uncertainty over going concern: the directors say further funding is needed before the end of 2026, even after a £2.6m Equity raise at 0.35 pence a share in June. It is a story of real operational progress set against a persistent funding gap.
Latest development: Olink certification opens a services Revenue line
On 11 August 2026 Verici announced that its CAP-accredited, CLIA-certified laboratory had become an Olink Certified Service Provider. Olink is a widely used platform for measuring protein biomarkers, and the certification allows Verici to offer Olink-based assay services for biomarker discovery, algorithm development and clinical-trial sample analysis, for its own pipeline and for external customers.
No financial terms were disclosed. The importance is strategic: the certification lets Verici monetise laboratory and bioinformatics infrastructure built for its own tests while proprietary volumes grow. The company cited a recent pharmaceutical collaboration analysing GLP-1 clinical-trial samples as proof that large partners already use its capabilities.
Chief operating officer Patti Connolly said the certification "reflects the strength of our laboratory team and our commitment to scientific excellence", pointing to Verici's "deep bioinformatics expertise and a CAP/CLIA/ISO quality system framework".
It followed another milestone on 24 June 2026, when New York State's Clinical Laboratory Evaluation Program approved Tutivia. New York is among the most demanding reviewers of laboratory-developed tests, and the approval means Tutivia can be ordered from every US state. New York alone performed more than 2,000 kidney transplants in 2025.
What Verici Dx does
Verici Dx is an immuno-diagnostics developer focused on kidney transplantation. Its tests sequence RNA from a patient's blood and apply machine-learning algorithms to gauge immune activity against the transplanted kidney. The United States is the principal market, served from a laboratory in Pennsylvania, and the company reports in US dollars despite its AIM listing.
Tutivia, the lead product, classifies post-transplant patients as high or low risk of acute rejection, aiming to catch rejection earlier and avoid unnecessary biopsies. Medicare covers it at $2,650 per test, 17 state Medicaid programmes reimburse it, and a February 2026 contract with Blue Cross Blue Shield of Illinois extended coverage to a network the company says reaches 118 million members.
Clarava, a pre-transplant risk-assessment test, is licensed globally to Thermo Fisher Scientific, now moving into early-adopter sales; Verici received a $0.8m milestone in FY25 and could earn further volume-based milestones and royalties. Protega, targeting long-term graft outcomes and fibrosis, is in clinical validation with a research-use-only launch planned before the end of FY26. The Olink certification adds contract laboratory services as a fourth revenue stream.
FY25 results: Tutivia revenue arrives, losses widen, going-concern flag raised
For the year ended 31 December 2025 (reported 29 June 2026), revenue rose to $3.7m from $3.3m. The mix changed markedly: Tutivia contributed $2.9m against nil a year earlier, while licence income fell to $0.8m from $3.3m on the timing of Thermo Fisher milestones. Tests ordered rose 250% to 1,173 (FY24: 334).
Higher commercial spending pushed the operating loss to $6.97m (FY24: $6.11m) and the loss before tax to $6.92m (FY24: $5.87m); adjusted EBITDA loss widened to $6.2m from $5.4m. Loss per share fell to 0.9 US cents from 2.5 cents, but only because the share count swelled after a $7.9m net equity raise in July 2025. Year-end cash was $3.34m (FY24: $4.06m), while trade receivables climbed to $1.96m from $0.50m.
By 31 March 2026 unaudited net cash had fallen to roughly $1.3m, prompting the June placing of 700 million shares at 0.35 pence, a 17.6% discount, plus a retail offer that lifted gross proceeds to about £2.6m, said to fund operations through at least the end of 2026. Management guided to FY26 revenue of $5.1m; the first quarter delivered 392 Tutivia tests, up 32% on the fourth quarter and 34% year on year, with seven new transplant centres ordering.
Chief executive Sara Barrington said Verici was "proud to have achieved substantial growth in FY25, reflected in the continued adoption of Tutivia and an increase in sales across the year".
What could drive the stock next?
The most visible near-term catalyst is the half-year report for the six months to 30 June 2026, together with any quarterly Volume update. Investors will want evidence that the first-quarter run-rate of roughly 130 tests a month has kept climbing towards the level implied by $5.1m of guided revenue.
Thermo Fisher's progress with Clarava is the biggest external swing factor: milestone or Royalty income would arrive at high Margin and directly ease the funding position. A research-use-only Protega launch before year-end would broaden the product story, the Olink services line could Yield the first non-transplant contracts, and further payor agreements or Medicaid approvals would widen the reimbursable patient pool.
Risks investors should watch
Funding is the dominant risk. The directors state that additional Capital will be needed before the end of 2026 and that there is "no guarantee that sufficient cash inflows from the Fundraising or other sources will be forthcoming in the timeframe required". Verici raised equity in July 2025 and again in June 2026 at 0.35 pence, when the 700 million placing shares alone equalled 47% of the existing share capital; at that price the enlarged company, with roughly 2.2 billion shares, was worth under £8m, leaving little cushion for another discounted raise.
Tutivia accounted for around 80% of FY25 revenue, while licence income is lumpy and outside Verici's control. Reimbursement policy for US laboratory-developed tests can change, receivables of nearly $2m against $3.7m of revenue point to slow collections, larger rivals such as CareDx and Natera compete hard in transplant surveillance, and sterling shareholders carry dollar exposure.
Outlook
Verici Dx (LSE:VRCI) has a reimbursed product, a customer base covering about a fifth of US kidney transplants, national regulatory clearance and a Blue-Chip licensing partner. FY26 guidance of $5.1m implies revenue growth of nearly 40%, and the Olink certification offers a way to sweat existing assets.
Yet the accounts are explicit that the money runs out without further inflows before 2026 ends. The interim results and quarterly test volumes will show whether commercial growth is closing the gap fast enough, and whether Thermo Fisher delivers milestones that change the equation. Every update deserves reading through the lens of cash burn and dilution as much as adoption.






Please wait processing your request...